Peptiligases enable a more economical manufacturing of linear Peptide Drugs and Antibody Drug Conjugates


The potential

Site-directed mutagenesis and cloning can produce peptiligases dedicated to highly selective coupling of specific peptide fragments.

This technology offers an entry into economic manufacturing processes for both linear peptide drugs and antibody drug conjugates (ADCs). The potential of the peptiligase technology however extends far beyond linear peptides and ADCs, to areas such as macrocyles (cyclotides) and conjugated dual inhibitors. We wish to explore such opportunities with interested customers and clients.

  • EnzyTag’s peptide synthesis technology (“CEPS” or “Chemo Enzymatic Peptide Synthesis”) is a solvent-free adjunct to solid-phase synthesis (SPPS).
  • CEPS generates significantly higher yields than SPPS (>2x) in the synthesis of long or complex peptides, and can reduce costs associated with peptide synthesis by up to 50%.
  • CEPS technology is capable of synthesizing >90% marketed pharmaceutical peptides, is commercially scalable and requires very little capex to implement with existing SPPS equipment and technologies.
  • Bioconjugation technology (“PECON” or “Protein Enzymatic Conjugation”) is an extrapolation of CEPS which uses ligases to selectively and highly efficiently couple a broad variety of peptides and proteins to each other.
  • Technology has significant applications in the synthesis of antibody drug conjugates (“ADC”), an emerging and rapidly growing pharmaceutical class, and in the generation of new chemical entities.
  • A key advantage of PECON over existing bioconjugation technologies is that it produces single, monodisperse products for simplified CMC and PK/PD.

Leading references outlining the technology include:

Please feel free to contact us

EnzyTag is open to further discussions on technology licensing for commercial purposes.

We use cookies to ensure that our website runs as smoothly as possible and to analyze web traffic. If you continue to use the website, you agree with our Privacy Policy. I agree